CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 109-120 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.

Shadman M; Ahlstrom J; Gutierrez M; Nastoupil L; Porter D; Schmitt A; Zitella L; Graff T

2026PubMedDirectly related

TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.

Cheng C; Liang T; Yao P; Wang W; Chen H; Li X; Tian Y; Wang J; Yan N; Xie D; Qiu F; Tan S

Jan 1, 2026Science advances

2026PubMedSupporting evidence

Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.

Asano Y; Veatch JR; Sung CJ; Tang TH; Mazziotta F; Natsuki S; McAfee M; Bakhtiari J; Lee B; Martin L; Rizzi A; Zhang T; Smith CW; Paulson KG; Schmitt TM; Newell EW; Elz AE; Chen DG; Su Y; Gustafson HH; Yeung CCS; Seaton B; Hunter D; Koelle DM; Bhatia S; Hall ET; Voillet V; Cao J; Gooley T; Greenberg PD; Gottardo R; Oda SK; Nghiem P; Chapuis AG

Jan 1, 2026Science translational medicine

2026PubMedDirectly related

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

Nikolaou V; Koumaki D; Perrot A; Kastritis E; Beylot-Barry M; Sibaud V

Jan 1, 2026Clinical lymphoma, myeloma & leukemia

2026PubMedDirectly related

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

Grasso A; Mishra AK; Silva J; Amrolia PJ

Jan 1, 2026Pediatrics

2026PubMedSupporting evidence

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.

Huang M; Zhang J; Huang H; Liu L; Zou Y

Jan 1, 2026Frontiers in immunology

2026PubMedSupporting evidence

In vivo genome-wide CRISPR screens identify FOXR1 as a suppressor of CD8(+) T cell antitumor immunity.

Yang X; Ouyang H; Xu H; Peng L; Cui J; Zhang B; Huang B; Wang C; Li G; Cao X

Jan 1, 2026Proceedings of the National Academy of Sciences of the United States of America

2026PubMedSupporting evidence

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

Dumbrava EE; Oh DY; Ryu MH; Calvo E; Garralda E; Chung WP; Bai LY; Rojas K; Yildirim O; Masciari S; Mi G; Wang L; Rotolo F; Gailhac S; Attieh E; Kanlikilicer P; Buday B; Perez R; Rharbaoui F; Abbadessa G; Moreno V

Jan 1, 2026Journal for immunotherapy of cancer

2026PubMedSupporting evidence

[Advances in single cell omics applications in mantle cell lymphoma].

Wang C; Zhang Q; Cao X

Jan 1, 2026Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

2026PubMedDirectly related

Simultaneous gene engineering of T cells with multiple neoantigen-specific T cell receptors for adoptive cell transfer.

Magna M; Levy L; Csomos K; Dinerman AJ; Hakim AA; Levin N; Kim SP; Zacharakis N; Parikh NB; Bui BD; Bhasin A; Beyer RK; Goff SL; Lowery FJ; Rosenberg SA; Krishna S

Jan 1, 2026Molecular therapy. Advances

2026PubMedSupporting evidence

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Panozzo B; Robinson S; Minson AG; Li J; Baldwin K; Scott HW; Oliaro J; Wong AJN; van der Linde S; O'Leary NL; Thompson PA; Seymour JF; Anderson MA; Tam CS; Harrison SJ; Dickinson MJ; Westerman DA; Dowling MR

Jan 1, 2026British journal of haematology

2026PubMedDirectly related

From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.

Wu S; Shen Y; Tong X; Nian S; Yang P

Jan 1, 2026Critical reviews in oncology/hematology